U.S. court rules for Teva in migraine patent dispute with Eli Lilly
Israel stocks ease; Teva loses patent ruling - MarketWatch
Teva Pharmaceuticals stock falls 11% after earnings miss - MarketWatch
Teva Poised to Get a Big Boost in Generics - WSJ
Three health-care deals today are paying huge premiums - MarketWatch
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Pharmaceuticals - Wikipedia
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva appoints Dipankar Bhattacharjee as Prez, CEO Global Generic Group - The Economic Times
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Opinion: These 3 stocks may be the only true value plays left - MarketWatch
Israeli stocks rise; Brainsway, Ratio Oil off - MarketWatch
Israel stocks steady; Teva settles with Takeda - MarketWatch
Teva Pharmaceutical Industries Ltd. ADR, TEVA Quick Chart - (NYS) TEVA, Teva Pharmaceutical Industries Ltd. ADR Stock Price - BigCharts.com
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Israel stocks fall for fifth day; Teva rises - MarketWatch
Leaner, More Agile Teva Sees Brighter Days Ahead
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Israel stocks up; FTC eyes Teva-Cephalon deal - MarketWatch
